Pharmacogenomics Before Surgery: Why Genetic Testing Can Improve Your Pain Management

You are scheduled for knee replacement next month. Your surgeon mentions post-operative pain management — you will get a combination of opioids and anti-inflammatories to control pain during recovery. What neither of you knows, unless you have been genetically tested, is whether those specific medications will actually work in your body.

About 6–10% of people of European descent cannot activate codeine or tramadol at all due to a CYP2D6 enzyme deficiency. Another 10–40% (depending on ethnicity) carry an OPRM1 variant that reduces opioid receptor binding, meaning standard morphine doses provide inadequate relief. These are not rare edge cases — in a surgical ward of 20 patients, several will have a genetic profile that changes how their pain should be managed.

Pharmacogenomic testing before surgery identifies these variables in advance, giving your surgical team the information they need to choose the right medications at the right doses — before the first incision.

Why Genetics Matter Before Surgery

Post-surgical pain management relies on a relatively small set of medications, and several of them have strong pharmacogenomic evidence. Knowing your genetic profile changes three specific clinical decisions.

Opioid Activation: CYP2D6

Codeine and tramadol are prodrugs — they are pharmacologically inactive until your liver converts them to their active forms (morphine and O-desmethyltramadol, respectively). The enzyme responsible is CYP2D6. Your CYP2D6 metabolizer status determines the outcome:

• Poor metabolizers (~6–10% of European populations) produce little or no CYP2D6 enzyme. Codeine provides zero pain relief for these patients. Tramadol is equally ineffective. Prescribing either drug after surgery wastes critical recovery time while the patient suffers unnecessarily.
• Ultrarapid metabolizers (~1–2% of European populations, higher in North African and Middle Eastern populations) convert prodrugs too quickly, creating dangerously high levels of the active metabolite. The FDA has issued a boxed warning about codeine in ultrarapid metabolizers due to risk of respiratory depression.
• Normal and intermediate metabolizers respond to codeine and tramadol as expected, though intermediate metabolizers may experience slightly reduced efficacy.

The bottom line: if your surgical team plans to prescribe codeine or tramadol after your procedure, your CYP2D6 status determines whether that plan will work.

Opioid Receptor Sensitivity: OPRM1

Even when an opioid is properly activated, it still needs to bind to your mu-opioid receptors to reduce pain. The OPRM1 A118G variant (rs1799971) reduces receptor expression and binding affinity. Clinical studies consistently show that G-allele carriers require 30–50% more morphine for equivalent post-operative analgesia.

Without genetic testing, this typically manifests as a patient who keeps pressing the PCA (patient-controlled analgesia) button and reporting inadequate pain control — leading to delays, dose escalation, and sometimes suspicion of drug-seeking behavior. Knowing the OPRM1 status in advance eliminates this entirely.

NSAID Safety: CYP2C9

Non-steroidal anti-inflammatory drugs are a cornerstone of multimodal post-surgical pain management. Celecoxib (Celebrex), ibuprofen, and meloxicam are all metabolized by CYP2C9. Poor metabolizers of CYP2C9 clear these drugs more slowly, leading to higher sustained blood levels and increased risk of gastrointestinal bleeding and cardiovascular events.

CPIC guidelines recommend dose reductions or alternative NSAIDs for CYP2C9 poor metabolizers — a recommendation that is particularly relevant in the post-surgical context where NSAIDs are often prescribed for days or weeks.

Which Medications Are Affected

Here are the specific pre-operative and post-operative medications with pharmacogenomic implications:

• Codeine — CYP2D6 prodrug. No effect in poor metabolizers. Toxicity risk in ultrarapid metabolizers.
• Tramadol — CYP2D6 prodrug. Same activation pathway as codeine. Poor metabolizers get minimal analgesia.
• Hydrocodone — partially activated by CYP2D6 to hydromorphone. Poor metabolizers may experience reduced efficacy.
• Morphine, fentanyl, oxycodone — all bind to the mu-opioid receptor encoded by OPRM1. A118G carriers may need higher doses.
• Celecoxib — metabolized by CYP2C9. Poor metabolizers require dose reduction per CPIC guidelines.
• Ondansetron (Zofran) — the most commonly prescribed anti-nausea medication during and after surgery. Metabolized by CYP2D6. Ultrarapid metabolizers may clear it too quickly, reducing its effectiveness.

The Pre-Op Pharmacogenomic Checklist

If you want to use pharmacogenomic information before your procedure, follow these practical steps:

1. Get tested before your procedure date. If you have 23andMe or AncestryDNA raw data, you can generate a pharmacogenomic report in minutes. If you need clinical-grade testing, allow 1–2 weeks for lab results.
2. Review your results. Focus on CYP2D6 metabolizer phenotype, OPRM1 receptor status, and CYP2C9 metabolizer phenotype. Understanding what these mean is covered in our guide to reading your report.
3. Share results with your anesthesiologist. Do this during your pre-operative consultation, not on the day of surgery. The clinician summary included in the report is designed to be reviewed in under a minute.
4. Bring a printed copy to the hospital. Even if your anesthesiologist reviewed the results during pre-op, the provider managing your post-operative pain may be different. Having a copy in your chart ensures continuity.
5. Ask specific questions. "Given my CYP2D6 status, will codeine/tramadol work for me?" is a concrete question your surgeon can act on. "I had genetic testing" without specifics is less useful.

How to Get Tested

There are two main paths to pharmacogenomic testing before surgery:

Option 1: Reuse existing DNA data. If you have already taken a 23andMe or AncestryDNA test, your raw data file contains the genetic positions needed for pharmacogenomic analysis. DecodeMyBio's Pain & Anesthesia Report extracts CYP2D6, OPRM1, COMT, and other pain-relevant genes from this data — $39, results in minutes. This is the fastest and most affordable option. Learn more about at-home pharmacogenomic testing.

Option 2: Clinical pharmacogenomic panel. If you do not have consumer DNA data, your doctor can order a clinical PGx test (such as GeneSight, Tempus, or OneOme). These typically cost $250–$2,000+ depending on insurance, and results take 1–2 weeks. See our pharmacogenomic testing cost breakdown for details.

Either approach gives you the key information. The advantage of reusing consumer DNA data is speed and cost — you can have results before your next appointment rather than waiting for a lab.